CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury

Nature Communications

Volumn 6, Issue , 2015, Pages

  Akahori, Hirokuni ^a   Karmali, Vinit ^a   Polavarapu, Rohini ^a   Lyle, Alicia N ^a   Weiss, Daiana ^a   Shin, Eric ^a   Husain, Ahsan ^a   Naqvi, Nawazish ^a   Van Dam, Richard ^a   Habib, Anwer ^a   Choi, Cheol Ung ^a,b   King, Adrienne L ^c   Pachura, Kimberly ^a   Taylor, W Robert ^a,d,e   Lefer, David J ^f   Finn, Aloke V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Korea University College of Medicine   (South Korea)

^c KENNESAW STATE UNIVERSITY   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

^e GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^f LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BETA DYSTROGLYCAN; CD163 ANTIGEN; CYTOKINE; FRUCTOSE BISPHOSPHATE ALDOLASE; GALACTOSE; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOSIN HEAVY CHAIN; NOTCH RECEPTOR; TUMOUR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 1; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TNFSF12 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

BLOOD; CELLS AND CELL COMPONENTS; IMMUNE RESPONSE; INJURY; MEMBRANE; MUSCLE; MUTATION; PROTEIN; REGENERATION; RODENT; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; IMMUNOHISTOCHEMISTRY; ISCHEMIA; LIMB ISCHEMIA; MITOCHONDRIAL RESPIRATION; MOUSE; MUSCLE REGENERATION; MUSCLE STEM CELL; NONHUMAN; PHENOTYPE; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; SATELLITE CELL; SCINTIGRAPHY; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REGENERATION; UPREGULATION; ANIMAL; KNOCKOUT MOUSE; MACROPHAGE; MALE; METABOLISM; PHYSIOLOGY; RANDOMIZATION; REGENERATION; REPERFUSION INJURY; SKELETAL MUSCLE;

MUS;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; MACROPHAGES; MALE; MICE, KNOCKOUT; MUSCLE, SKELETAL; NF-KAPPA B; RANDOM ALLOCATION; RECEPTORS, CELL SURFACE; RECEPTORS, NOTCH; REGENERATION; REPERFUSION INJURY; TUMOR NECROSIS FACTORS;

EID: 84939150626     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8792     Document Type: Article

References (40)

1. Lloyd-Jones, D. et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, 480-486 (2009).
2. Lambert, J. M., Lopez, E. F. & Lindsey, M. L. Macrophage roles following myocardial infarction. Int. J. Cardiol. 130, 147-158 (2008).
3. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23-35 (2003).
4. Pulford, K. et al. A monocyte/macrophage antigen recognized by the four antibodies GHI/61, Ber-MAC3, Ki-M8 and SM4. Immunology 75, 588-595 (1992).
5. Kristiansen, M. et al. Identification of the haemoglobin scavenger receptor. Nature 409, 198-201 (2001).
6. Droste, A. & Sorg, C. Hogger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem. Biophys. Res. Commun. 256, 110-113 (1999).
7. Moller, H. J., Nielsen, M. J., Maniecki, M. B., Madsen, M. & Moestrup, S. K. Soluble macrophage-derived CD163: A homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding. Immunobiology 215, 406-412 (2010).
8. Timmermann, M. & Hogger, P. Oxidative stress and 8-iso-prostaglandin F(2alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free. Radic. Biol. Med. 39, 98-107 (2005).
9. Moller, H. J. Soluble CD163. Scand. J. Clin. Lab. Invest. 72, 1-13 (2012).
10. Marchetti, V. et al. Differential macrophage polarization promotes tissue remodeling and repair in a model of ischaemic retinopathy. Sci. Rep. 1, 76 (2011).
11. Maecker, H. et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 123, 931-944 (2005).
12. Chicheportiche, Y. et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272, 32401-32410 (1997).
13. Brown, S. A., Richards, C. M., Hanscom, H. N. & Feng, S. L. Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem. J. 371, 395-403 (2003).
14. Burkly, L. C., Michaelson, J. S., Hahm, K., Jakubowski, A. & Zheng, T. S. TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease. Cytokine 40, 1-16 (2007).
15. Burkly, L. C. & Dohi, T. The TWEAK/Fn14 pathway in tissue remodeling: For better or for worse. Adv. Exp. Med. Biol. 691, 305-322 (2011).
16. Girgenrath, M. et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J. 25, 5826-5839 (2006).
17. Benedito, R. et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 484, 110-114 (2012).
18. Conboy, I. M. & Rando, T. A. The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev. Cell 3, 397-409 (2002).
19. Landor, S. K. et al. Hypo-and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms. Proc. Natl Acad. Sci. USA 108, 18814-18819 (2011).
20. Xu, H. et al. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat. Immunol. 13, 642-650 (2012).
21. Bash, J. et al. Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. EMBO J. 18, 2803-2811 (1999).
22. Maniati, E. et al. Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. J. Clin. Invest. 121, 4685-4699 (2011).
23. Tirziu, D. et al. Endothelial nuclear factor-kappaB-dependent regulation of arteriogenesis and branching. Circulation 126, 2589-2600 (2012).
24. May, M. J. et al. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289, 1550-1554 (2000).
25. Mittal, A. et al. Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. Am. J. Pathol. 177, 1732-1742 (2010).
26. Bover, L. C. et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: Potential biological implications. J. Immunol. 178, 8183-8194 (2007).
27. Enwere, E. K. et al. TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway. Sci. Signal. 5, ra75 (2012).
28. Roos, C. et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J. Immunol. 185, 1593-1605 (2010).
29. Urbonaviciene, G. et al. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis 219, 892-899 (2011).
30. Fick, A. et al. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J. Biol. Chem. 287, 484-495 (2012).
31. Brown, S. A., Ghosh, A. & Winkles, J. A. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J. Biol. Chem. 285, 17432-17441 (2010).
32. Ogura, Y., Mishra, V., Hindi, S. M., Kuang, S. & Kumar, A. Proinflammatory cytokine tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) suppresses satellite cell self-renewal through inversely modulating Notch and NF-kappaB signaling pathways. J. Biol. Chem. 288, 35159-35169 (2013).
33. Noguera-Troise, I. et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032-1037 (2006).
34. Sjolund, J. et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J. Clin. Invest. 118, 217-228 (2008).
35. Fukuda, D. et al. Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc. Natl Acad. Sci. USA. 109, E1868-E1877 (2012).
36. Shen, X. Z. et al. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am. J. Pathol. 170, 2122-2134 (2007).
37. Hodara, R. et al. Overexpression of catalase in myeloid cells causes impaired postischemic neovascularization. Arterioscler. Thromb. Vasc. Biol. 31, 2203-2209 (2011).
38. Finn, A. V. et al. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: Requirement for mTOR/Akt2 in PPARgamma activation. Circ. Res. 105, 1003-1012 (2009).
39. Venkatraman, A. et al. Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity. J. Biol. Chem. 279, 22092-22101 (2004).
40. Liang, W. C. et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951-961 (2006).